Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

miR-449b-5p from adipose-derived mesenchymal stem cell-derived exosomes targets IGF1R to alleviate airway inflammation and improve airway smooth muscle cell dysfunction in children with asthma.

Sui S., Yang L., Ji D., Guo J.

Laboratory Study on Chronic Inflammation, published in J Immunol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
J Immunol (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41986878
DOI
10.1093/jimmun/vkaf376

Abstract (original English)

This study investigated the protective effect of miR-449b-5p from adipose-derived mesenchymal stem cell-derived exosomes (ADSC-Exos) targeting type 1 insulin-like growth factor receptor (IGF1R) on airway smooth muscle cells (ASMCs) and further investigated its mechanism of action. ADSC-Exos were isolated and characterized. Cellular uptake of ADSC-Exos by ASMCs was observed. Differences in serum miR-449b-5p expression levels between healthy children and asthmatic children were detected by RT-qPCR. The possible binding sites of miR-449b-5p and IGF1R were identified and then verified. The proliferation of ASMCs was determined by MTT assay and EdU assay. Cell cycle of ASMCs was measured by flow cytometry. Cell contraction of ASMCs was evaluated by inverted microscopy. IL-4, IL-5, and IFN-γ were measured by ELISA to evaluate the inflammatory response of ASMCs. ADSC-Exos exerted therapeutic effects on ASMCs by effectively inhibiting proliferation, cell contraction, and inflammatory response. miR-449b-5p upregulation in ASMCs effectively inhibited the promoting effect of PDGF-BB on cellular proliferation and contraction, while IGF1R upregulation showed the opposite effect. miR-449b-5p in ADSC-Exos targeted IGF1R to alleviate airway inflammation in asthma and improve ASMC dysfunction. ADSC-Exos carrying miR-449b-5p improve ASMC dysfunction, excessive proliferation, and inflammatory res

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansMicroRNAsAsthmaExosomesMesenchymal Stem CellsChildMyocytes, Smooth MuscleReceptor, IGF Type 1Cell ProliferationMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research